Revvity, Inc. (RVTY) PE Ratio: 46.58
Is Revvity, Inc.’s P/E ratio high or low?
Revvity, Inc.'s P/E ratio of 46.58 is 38% above its 5-year average of 33.73, around the middle of its 5-year range (13.79–89.73).
As of Wednesday, June 17, 2026. 6.03% above its 12-month average of 43.93.
PE Ratio (46.58) = Close Price ($97.82) / Diluted TTM EPS ($2.10)
RVTY PE Ratio Chart
RVTY Average PE Ratio Chart
RVTY Current vs Average PE Ratio Chart
RVTY PE Ratio Metrics
PE RATIO
46.58
PE RATIO AVG TTM
43.93
PE RATIO AVG 3Y
41.05
PE RATIO AVG 5Y
33.51
PE RATIO AVG 10Y
34.81
PE RATIO AVG 15Y
34.90
PE RATIO AVG 20Y
31.35
CURRENT VS TTM AVG
+6.03%
CURRENT VS 3Y AVG
+13.48%
CURRENT VS 5Y AVG
+38.99%
CURRENT VS 10Y AVG
+33.82%
CURRENT VS 15Y AVG
+33.48%
CURRENT VS 20Y AVG
+48.56%
RVTY Competitors' PE Ratio
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Revvity, Inc. (RVTY) | $10.91B | 46.58 | 43.93 | 41.05 | 33.51 |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | N/A | 33.48 | 14.63 | 25.08 |
| Baxter International Inc. (BAX)vs › | $10.19B | N/A | 44.53 | 34.41 | 37.43 |
| The Cooper Companies, Inc. (COO)vs › | $12.69B | 55.13 | 37.36 | 47.65 | 31.41 |
| Align Technology, Inc. (ALGN)vs › | $12.86B | 30.12 | 29.23 | 42.60 | 47.58 |
| Solventum Corporation (SOLV)vs › | $12.91B | 9.13 | 18.48 | 17.02 | 17.02 |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.90B | N/A | 225.66 | 91.39 | 72.20 |
| Medpace Holdings, Inc. (MEDP)vs › | $13.05B | 28.71 | 33.93 | 33.24 | 33.12 |
| Tempus AI, Inc. (TEM)vs › | $8.51B | N/A | N/A | N/A | N/A |
| DaVita Inc. (DVA)vs › | $13.46B | 21.02 | 14.51 | 15.87 | 14.84 |
P/E vs. its own history
At 46.6, P/E is richer than usual, sitting higher than 78% of its 20-year history.
20-year low
9.7
median
29.9
20-year high
505844310146254080.0
P/E Comparison
Trailing P/E
46.6
Forward P/E
16.8
Forward P/E Calculation
View All Analyst EstimatesForward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$97.82
Forward EPS (Est.)
$5.83
Forward P/E
16.78
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
Revvity, Inc. PE Ratio Formula & Definition
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Revvity, Inc. PE Ratio FAQ
- What is the P/E ratio for Revvity, Inc. (RVTY)?
- The P/E ratio for RVTY stock is 46.58.
- Is Revvity, Inc.'s P/E ratio high or low?
- Revvity, Inc.'s P/E ratio of 46.58 is 38% above its 5-year average of 33.73, around the middle of its 5-year range (13.79–89.73).
- What is the TTM average P/E ratio for Revvity, Inc. (RVTY)?
- The TTM average P/E ratio for RVTY stock is 43.93.
- What is the 3Y average P/E ratio for Revvity, Inc. (RVTY)?
- The 3Y average P/E ratio for RVTY stock is 41.05.
- What is the 5Y average P/E ratio for Revvity, Inc. (RVTY)?
- The 5Y average P/E ratio for RVTY stock is 33.51.
- What is the 10Y average P/E ratio for Revvity, Inc. (RVTY)?
- The 10Y average P/E ratio for RVTY stock is 34.81.
- What is the 15Y average P/E ratio for Revvity, Inc. (RVTY)?
- The 15Y average P/E ratio for RVTY stock is 34.90.
- What is the 20Y average P/E ratio for Revvity, Inc. (RVTY)?
- The 20Y average P/E ratio for RVTY stock is 31.35.
Revvity, Inc. PE Ratio History
| DATE | PE RATIO |
|---|---|
| 2026-06-17 | 46.58 |
| 2026-06-16 | 48.20 |
| 2026-06-15 | 47.88 |
| 2026-06-12 | 47.46 |
| 2026-06-11 | 48.34 |
| 2026-06-10 | 48.23 |
| 2026-06-09 | 49.59 |
| 2026-06-08 | 47.76 |
| 2026-06-05 | 46.84 |
| 2026-06-04 | 48.76 |
| 2026-06-03 | 48.13 |
| 2026-06-02 | 47.80 |
| 2026-06-01 | 47.87 |
| 2026-05-29 | 49.79 |
| 2026-05-28 | 48.20 |
| 2026-05-27 | 46.09 |
| 2026-05-26 | 46.11 |
| 2026-05-22 | 46.17 |
| 2026-05-21 | 45.42 |
| 2026-05-20 | 45.14 |
| 2026-05-19 | 45.65 |
| 2026-05-18 | 45.47 |
| 2026-05-15 | 44.75 |
| 2026-05-14 | 45.90 |
| 2026-05-13 | 45.24 |
| 2026-05-12 | 47.29 |
| 2026-05-11 | 47.47 |
| 2026-05-08 | 48.45 |
| 2026-05-07 | 47.42 |
| 2026-05-06 | 47.53 |
| 2026-05-05 | 44.28 |
| 2026-05-04 | 41.50 |
| 2026-05-01 | 41.58 |
| 2026-04-30 | 41.55 |
| 2026-04-29 | 39.46 |
| 2026-04-28 | 40.86 |
| 2026-04-27 | 41.64 |
| 2026-04-24 | 41.62 |
| 2026-04-23 | 41.81 |
| 2026-04-22 | 45.23 |
| 2026-04-21 | 45.22 |
| 2026-04-20 | 44.63 |
| 2026-04-17 | 45.07 |
| 2026-04-16 | 42.95 |
| 2026-04-15 | 44.56 |
| 2026-04-14 | 44.86 |
| 2026-04-13 | 44.44 |
| 2026-04-10 | 43.07 |
| 2026-04-09 | 43.39 |
| 2026-04-08 | 43.37 |
| 2026-04-07 | 42.11 |
| 2026-04-06 | 42.37 |
| 2026-04-02 | 42.67 |
| 2026-04-01 | 42.18 |
| 2026-03-31 | 42.03 |
| 2026-03-30 | 40.67 |
| 2026-03-27 | 40.25 |
| 2026-03-26 | 41.79 |
| 2026-03-25 | 42.14 |
| 2026-03-24 | 41.96 |
| 2026-03-23 | 41.81 |
| 2026-03-20 | 41.23 |
| 2026-03-19 | 41.14 |
| 2026-03-18 | 40.74 |
| 2026-03-17 | 41.91 |
| 2026-03-16 | 41.49 |
| 2026-03-13 | 41.05 |
| 2026-03-12 | 40.66 |
| 2026-03-11 | 43.00 |
| 2026-03-10 | 43.32 |
| 2026-03-09 | 44.19 |
| 2026-03-06 | 43.82 |
| 2026-03-05 | 46.33 |
| 2026-03-04 | 47.25 |
| 2026-03-03 | 46.03 |
| 2026-03-02 | 45.86 |
| 2026-02-27 | 47.16 |
| 2026-02-26 | 47.50 |
| 2026-02-25 | 46.81 |
| 2026-02-24 | 46.83 |
| 2026-02-23 | 48.69 |
| 2026-02-20 | 50.30 |
| 2026-02-19 | 50.09 |
| 2026-02-18 | 49.00 |
| 2026-02-17 | 47.65 |
| 2026-02-13 | 48.14 |
| 2026-02-12 | 47.91 |
| 2026-02-11 | 50.69 |
| 2026-02-10 | 52.52 |
| 2026-02-09 | 51.55 |
| 2026-02-06 | 50.93 |
| 2026-02-05 | 49.89 |
| 2026-02-04 | 52.06 |
| 2026-02-03 | 50.70 |
| 2026-02-02 | 53.69 |
| 2026-01-30 | 54.55 |
| 2026-01-29 | 54.39 |
| 2026-01-28 | 55.72 |
| 2026-01-27 | 57.46 |
| 2026-01-26 | 57.51 |
| 2026-01-23 | 58.52 |
| 2026-01-22 | 59.03 |
| 2026-01-21 | 58.42 |
| 2026-01-20 | 56.10 |
| 2026-01-16 | 56.40 |
| 2026-01-15 | 57.82 |
| 2026-01-14 | 55.91 |
| 2026-01-13 | 55.22 |
| 2026-01-12 | 52.09 |
| 2026-01-09 | 52.36 |
| 2026-01-08 | 50.99 |
| 2026-01-07 | 51.63 |
| 2026-01-06 | 52.67 |
| 2026-01-05 | 51.17 |
| 2026-01-02 | 49.21 |
| 2025-12-31 | 48.51 |
| 2025-12-30 | 48.85 |
| 2025-12-29 | 48.69 |
| 2025-12-26 | 48.51 |
| 2025-12-24 | 48.52 |
| 2025-12-23 | 48.92 |
| 2025-12-22 | 49.02 |
| 2025-12-19 | 48.25 |
| 2025-12-18 | 48.26 |
| 2025-12-17 | 48.52 |
| 2025-12-16 | 48.27 |
| 2025-12-15 | 49.67 |
| 2025-12-12 | 50.38 |
| 2025-12-11 | 52.10 |
| 2025-12-10 | 51.90 |
| 2025-12-09 | 49.52 |
| 2025-12-08 | 50.03 |
| 2025-12-05 | 50.53 |
| 2025-12-04 | 51.41 |
| 2025-12-03 | 51.77 |
| 2025-12-02 | 51.50 |
| 2025-12-01 | 51.35 |
| 2025-11-28 | 52.35 |
| 2025-11-26 | 52.47 |
| 2025-11-25 | 52.93 |
| 2025-11-24 | 50.43 |
| 2025-11-21 | 49.27 |
| 2025-11-20 | 47.14 |
| 2025-11-19 | 46.25 |
| 2025-11-18 | 46.66 |
| 2025-11-17 | 45.65 |
| 2025-11-14 | 46.49 |
| 2025-11-13 | 46.83 |
| 2025-11-12 | 47.19 |
| 2025-11-11 | 47.28 |
| 2025-11-10 | 46.26 |
| 2025-11-07 | 45.51 |
| 2025-11-06 | 44.88 |
| 2025-11-05 | 46.41 |
| 2025-11-04 | 45.97 |
| 2025-11-03 | 39.42 |
| 2025-10-31 | 39.68 |
| 2025-10-30 | 38.59 |
| 2025-10-29 | 40.41 |
| 2025-10-28 | 40.90 |
| 2025-10-27 | 41.20 |
| 2025-10-24 | 41.93 |
| 2025-10-23 | 41.37 |
| 2025-10-22 | 40.57 |
| 2025-10-21 | 41.08 |
| 2025-10-20 | 40.41 |
| 2025-10-17 | 39.61 |
| 2025-10-16 | 39.86 |
| 2025-10-15 | 39.06 |
| 2025-10-14 | 38.64 |
| 2025-10-13 | 38.58 |
| 2025-10-10 | 37.44 |
| 2025-10-09 | 38.87 |
| 2025-10-08 | 38.91 |
| 2025-10-07 | 38.67 |
| 2025-10-06 | 39.59 |
| 2025-10-03 | 39.88 |
| 2025-10-02 | 38.78 |
| 2025-10-01 | 38.91 |
| 2025-09-30 | 37.17 |
| 2025-09-29 | 35.70 |
| 2025-09-26 | 35.64 |
| 2025-09-25 | 35.21 |
| 2025-09-24 | 35.83 |
| 2025-09-23 | 36.34 |
| 2025-09-22 | 36.58 |
| 2025-09-19 | 36.77 |
| 2025-09-18 | 37.21 |
| 2025-09-17 | 36.21 |
| 2025-09-16 | 36.16 |
| 2025-09-15 | 35.62 |
| 2025-09-12 | 35.14 |
| 2025-09-11 | 36.33 |
| 2025-09-10 | 34.98 |
| 2025-09-09 | 36.06 |
| 2025-09-08 | 36.58 |
| 2025-09-05 | 36.74 |
| 2025-09-04 | 36.34 |
| 2025-09-03 | 35.35 |
| 2025-09-02 | 37.26 |
| 2025-08-29 | 38.21 |
| 2025-08-28 | 37.83 |
| 2025-08-27 | 37.56 |
| 2025-08-26 | 38.68 |
| 2025-08-25 | 39.07 |
| 2025-08-22 | 39.92 |
| 2025-08-21 | 38.02 |
| 2025-08-20 | 38.88 |
| 2025-08-19 | 38.76 |
| 2025-08-18 | 38.03 |
| 2025-08-15 | 38.49 |
| 2025-08-14 | 37.93 |
| 2025-08-13 | 38.56 |
| 2025-08-12 | 37.31 |
| 2025-08-11 | 36.38 |
| 2025-08-08 | 36.82 |
| 2025-08-07 | 36.66 |
| 2025-08-06 | 36.42 |
| 2025-08-05 | 37.60 |
| 2025-08-04 | 34.92 |
| 2025-08-01 | 34.89 |
| 2025-07-31 | 34.76 |
| 2025-07-30 | 35.92 |
| 2025-07-29 | 37.35 |
| 2025-07-28 | 37.58 |
| 2025-07-25 | 40.99 |
| 2025-07-24 | 40.32 |
| 2025-07-23 | 39.32 |
| 2025-07-22 | 38.01 |
| 2025-07-21 | 35.87 |
| 2025-07-18 | 36.87 |
| 2025-07-17 | 37.79 |
| 2025-07-16 | 37.52 |
| 2025-07-15 | 37.92 |
| 2025-07-14 | 38.93 |
| 2025-07-11 | 40.13 |
| 2025-07-10 | 40.49 |
| 2025-07-09 | 39.59 |
| 2025-07-08 | 39.80 |
| 2025-07-07 | 39.03 |
| 2025-07-03 | 40.06 |
| 2025-07-02 | 39.90 |
| 2025-07-01 | 39.16 |
| 2025-06-30 | 38.24 |
| 2025-06-27 | 38.68 |
| 2025-06-26 | 39.06 |
| 2025-06-25 | 38.63 |
| 2025-06-24 | 38.11 |
| 2025-06-23 | 37.54 |
| 2025-06-20 | 37.56 |
| 2025-06-18 | 37.33 |
| 2025-06-17 | 37.23 |
| 2025-06-16 | 38.10 |
| 2025-06-13 | 36.98 |
| 2025-06-12 | 37.84 |
| 2025-06-11 | 37.99 |
| 2025-06-10 | 38.06 |
| 2025-06-09 | 36.72 |
| 2025-06-06 | 36.36 |
| 2025-06-05 | 35.78 |
Showing the most recent 260 of 5,031 data points. The chart above shows the full history.
About Revvity, Inc.
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Prahlad R. Singh